** Shares of drug developer Relmada Therapeutics fall 77.6% to 62 cents premarket
** Co says its depression treatment is "unlikely" to meet the main goal of a late-stage trial, according to an independent data monitoring committee's analysis
** Co was testing the treatment, REL-1017, as an additional treatment for major depressive disorder to be used in combination with other approved anti-depressants
** Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program - RLMD
** Co had about $54.1 million in cash and cash equivalents as of September 30, 2024
** Up to last close, stock down 33% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。